Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads In Renal Cell Carcinoma

Renal Cell Carcinoma for November/December 2018

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4

Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617

More must reads

Renal Cell Carcinoma for September/October 2018

No single genetic driver of metastases in ccRCC, Choueiri TK et al. Br J Cancer. 2018 May;118(9):1238-42.

Staging criteria for RCC with nodal involvement: Time to change?, Karam JA et al. Cancer. 2018 Oct 1. doi: 10.1002/cncr.31661.

RCC incidence rates stabilize while mortality rates drop, Saad AM et al. Clin Genitourin Cancer. 2018. doi: 10.1016/j.clgc.2018.10.002.

ADT and dementia in prostate cancer, Deka R et al. JAMA Oncol. 2018 Oct 11. doi: 10.1001/jamaoncol.2018.4423.

Pazopanib appears safe in mRCC and renal failure, Masini C et al. Clin Genitourin Cancer. 2018 Oct 1. doi: 10.1016/j.clgc.2018.10.001.

More must reads

Renal Cell Carcinoma for July/August 2018

Prognostic factors in PRCC identified, Polifka I et al. Hum Pathol. 2018 Aug 16. doi: 10.1016/j.humpath.2018.08.006.

Leptin expression may aid in differentiation of renal lesions, Gobe G et al. Pathology. 2018 Aug;50(5):504-10

Hypofractionated radiation offers 'tailored treatment' approach to RCC mets, Felice F et al. Crit Rev Oncol Hematol. 2018 Aug 1. doi: 10.1016/j.critrevonc.2018.06.002.

Concern over SREs rises with increasing incidence of metastatic RCC, Umer M et al. Ann Med Surg. 2018 Jan 21. doi: 10.1016/j.amsu.2018.01.002

Radioactive agent approved for adrenal tumors, FDA approves iobenguane I 131 injection (Azedra) for IV use for the treatment of pheochromocytoma or paraganglioma. 

More must reads

Pages